ClinicalTrialsFinder
RecruitingNCT07681323

Timing of ctDNA Testing in Advanced Breast Cancer

Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)

Sponsor

Geneplus-Beijing Co. Ltd.

Enrollment

400 participants

Start Date

Jul 8, 2026

Study Type

OBSERVATIONAL

Conditions

Advanced Breast Cancer

Summary

This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with advanced breast cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07681323

Related Trials

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT0612028363 locations

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT075243225 locations

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT0731880513 locations

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

NCT075910901 location